Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Siegel, David
Tran, Nguyet
Fu, Alan
Fowler, Jessica
Belani, Rajesh
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Funding for this research was provided by:
Amgen
Article History
Received: 23 December 2019
Revised: 21 May 2020
Accepted: 26 May 2020
First Online: 30 June 2020
Conflict of interest
: N.T., A.F., J.F., and R.B. are employees of and own stock in Amgen, Inc, developer of 2 BiTE® immunotherapies (AMG 420 and AMG 701) and 1 ADC (AMG 224) targeting BCMA. O.L. received grants/research support from Celgene, Amgen, BMS, and Karyopharm; received grants/research support, honoraria, and other from Janssen; received grants/research support and other for Takeda; received honoraria from Celgene, Amgen, and Adaptive Biotech; and received other from Merck. A.D. received honoraria and consulting or advisory role fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda, and EUSAPharma; and research grants from National Cancer Institute and Roche. D.S. received honoraria and consulting or advisory role fees from Celgene, Amgen, Merck, Janssen, BMS, Takeda, and Karyopharm; participated in speakers’ bureaus for Celgene, Amgen, Merck, Janssen, BMS, and Takeda; and received research funding from Celgene.